A new treatment for people with haemophilia A, developed at UCL, is offering a new quality of life for people with the debilitating disease.

The technology was developed by Professor Amit Nathwani (UCL Cancer Institute and Institute of Immunity & Transplantation) and his team at UCL and St. Jude Children’s Research Hospital, USA.

It was licensed by UCL Business (UCLB), the commercialisation company for UCL, to BioMarin Pharmaceuticals Inc. in 2013.

Find out more in the case study on the UCL Innovation & Enterprise website.

84

4/12/2024

This episode we explore Positive Impact. UCLB is helping to create a new generation of businesses from UCL academics specifically with positive societal impact at their heart. The commercialisation process can be a long road requiring financial, legal, and practical support. Nigel Campbell meets two inventors, Buffy Price Co-founder and COO of Carbon Re, an AI and Climate Tech company spinout from UCL and Cambridge, and Professor Pete Coffey from UCL Institute of Ophthalmology and Founder of Tenpoint Therapeutics; both who are on that journey on how their inventions might improve our future world. We also talk to Dr Anne Lane, CEO of UCLB to find out how UCLB finds the bright ideas which will improve lives, and what it takes to scale to a point where they are having true impact.

8

2/9/2024

In this episode, Katy Bruce, CFO of UCL Business, and Charu Gorasia, CFO of UCL, will discuss the mutually beneficial relationship between the technology transfer office, such as UCLB, and the university. They will dive into the research income financial cycle and how the commercialisation income is distributed back into the research ecosystem. This podcast will also cover the challenges around commercialisation income, how to tackle these and what does the future hold

5

11/17/2023

In the tenth episode, Dr Anne Lane, CEO of UCLB and Dr Chris Hollowood, CEO of Syncona Investment Management, discussed the collaboration between their respective organisations in commercialising research. Syncona is a leading healthcare investment company focused on creating, building and scaling a portfolio of global leaders in life science; and Chris has been instrumental in the foundation and the development of its gene therapy strategy. In this podcast, Anne and Chris discussed how Syncona came about, its close relationship with UCL and UCL Business, and what attracted Syncona to invest in four UCLB companies. Chris also discussed the tech transfer ecosystem and what is next for Syncona.

6

10/17/2023

In the ninth episode of this podcast series, Ana Lemmo Charnalia, Senior Business Manager at UCLB, is in conversation with Orla O’Donnell , Divisional Manager at the UCL Div of Biosciences and former Chief Operating Officer of Health Digital CIC, a Community Interest Company incorporated in 2015 to commercialise HeLP-Diabetes. It is also an opportunity to celebrate Professor Elizabeth Murray’s life, who led the development of HeLP-Diabetes. Join them in this discussion about their experiences and learnings from an early-stage social venture to the national roll-out of an online programme for people with Type 2 diabetes.

1

9/14/2023